Phathom Pharmaceuticals, Inc.
PHAT
$9.58
$0.404.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 110.16% | 150.30% | 216.93% | 460.30% | 1,049.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 110.16% | 150.30% | 216.93% | 460.30% | 1,049.81% |
| Cost of Revenue | 174.09% | 173.91% | 183.46% | 333.92% | 658.41% |
| Gross Profit | 100.53% | 146.53% | 222.57% | 485.20% | 1,146.76% |
| SG&A Expenses | -37.07% | -25.96% | -3.77% | 13.67% | 52.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.82% | -18.13% | 0.71% | 14.79% | 45.80% |
| Operating Income | 84.89% | 66.27% | 42.34% | 25.86% | -6.41% |
| Income Before Tax | 69.99% | 54.51% | 33.82% | 19.12% | -11.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.99% | 54.51% | 33.82% | 19.12% | -11.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.99% | 54.51% | 33.82% | 19.12% | -11.12% |
| EBIT | 84.89% | 66.27% | 42.34% | 25.86% | -6.41% |
| EBITDA | 85.04% | 66.38% | 42.40% | 25.90% | -6.43% |
| EPS Basic | 73.04% | 59.74% | 43.00% | 33.04% | 7.85% |
| Normalized Basic EPS | 73.04% | 59.75% | 43.00% | 33.03% | 7.85% |
| EPS Diluted | 73.04% | 59.74% | 43.00% | 33.04% | 7.85% |
| Normalized Diluted EPS | 73.04% | 59.75% | 43.00% | 33.03% | 7.85% |
| Average Basic Shares Outstanding | 11.75% | 13.35% | 15.46% | 20.94% | 21.26% |
| Average Diluted Shares Outstanding | 11.75% | 13.35% | 15.46% | 20.94% | 21.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |